Opicapone 50 mg

DRUG4 trials

Sponsors

Bial - Portela C S.A., University Hospital of Ferrara

Conditions

Effect of DrugParkinsonParkinson Disease

Phase 3

Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

CompletedNCT04978597

Bial - Portela C S.A.Parkinson

Start: 2021-05-31End: 2024-01-26Updated: 2025-03-12

Phase 4

OpiCapone Effect on Motor Fluctuations and pAiN

CompletedNCT04986982

Bial - Portela C S.A.Parkinson Disease

Start: 2021-02-25End: 2024-02-16Updated: 2025-03-28

Unknown Phase

Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

CompletedNCT06432309

University Hospital of FerraraEffect of Drug, Parkinson Disease

Start: 2022-07-01End: 2024-04-25Updated: 2025-03-03

REal-life ON PARKinson's - ITaly (REONPARK-IT)

Active, not recruitingNCT07403799

Bial - Portela C S.A.Parkinson Disease

Start: 2025-07-08End: 2029-06-30Updated: 2026-07-13

Related Papers

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations

Journal of Parkinson s Disease2026-04-17

Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial

European Journal of Neurology2025-01-015 citations